1547: Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica

Jeffrey Curtis¹, Kerri Ford², Stefano Fiore³, Danielle Isaman⁴, Lita Araujo⁵, Natalia Petruski-Ivleva⁶ and Fenglong Xie⁷, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Destin, FL, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Chapel Hill, NC, ⁵Sanofi, Cambridge, MA, ⁶Sanofi, Unknown, ⁷University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Interleukin-6 receptor (IL-6R) inhibition has been shown to be effective in giant cell arteritis but data are limited in polymyalgia rheumatica (PMR). We conducted a retrospective study to evaluate effectiveness of IL-6R inhibitors (IL-6Ri; sarilumab or tocilizumab) in 3^rd-line and 2^nd-line treatment of glucocorticoid (GC)-refractory PMR patients compared to conventional immunomodulatory (cIM) therapy.

Methods: Adults with PMR, defined as 1 inpatient or 2 outpatient claims with a PMR diagnosis ≥30 days apart, were identified from national fee-for-service Medicare (100% sample) data between 3/29/2016- to 6/30/2020. Included were those who initiated IL-6Ri or cIM as 2^nd-line and 3^rd-line therapy for PMR and had continuous enrollment for 180 days prior to therapy initiation (baseline). For 3^rd-line cohort, the index date was date of switch from cIM to IL-6Ri for the IL-6Ri group and switch from one cIM to another cIM for the cIM group. For 2^nd-line cohort, the index date was the date of initiation of IL-6Ri with no prior cIM for the IL-6Ri group and new use of cIM for the cIM group. A 180-day washout period for the index drug was applied to all cohorts. Patients were on GC on index date (≤25mg/day) and excluded if they had evidence of seropositive rheumatoid arthritis, other inflammatory arthritis or connective tissue disease, multiple sclerosis, or malignancy. Patients on IL-6Ri and cIM were matched 1:1 on age, sex, and GC dose category, and propensity score matching was used to adjust for potential confounders.

Outcomes assessed using adjusted Cox proportional hazards models included GC discontinuation; GC discontinuation or low dose GC (< 2mg/day); and non-persistence (discontinuation of IL-6Ri or cIM, or switch) in the 2^nd-line cohort, adjusting for residually imbalanced factors after matching. Censoring occurred at 1 year, death, 60 days before end of enrollment, or addition of comparator PMR therapy with additional censoring applied in sensitivity analysis for drug discontinuation and/or switching.

Results: After matching, 409 3^rd-line and 251 2^nd-line patients were included in the analysis. Post-match, patient characteristics were generally well balanced between cohorts, with small differences between exposure groups (Table 1). Median time from first PMR diagnosis to start of follow-up was approximately 1.75 years (3^rd-line) and 0.90 years (2^nd-line) and similar between groups. After matching and adjustment, patients receiving IL-6Ri were more likely to achieve GC discontinuation or low dose GC, compared to cIM patients (Table 2). Time to discontinuation (Figure) was significantly greater for IL-6Ri vs. cIM patients (p=0.029).

Conclusion: IL-6Ri therapy was more effective as a steroid sparing agent compared to cIM therapy for adult patients with PMR.





Disclosures: J. Curtis, Amgen, Bristol-Myers Squibb (BMS), CorEvitas, IlluminationHealth, Janssen, Lilly, Myriad, Novartis, Pfizer, Sanofi, UCB, Aqtual, Bendcare, FASTER, GlaxoSmithKlein (GSK), Labcorp, Scipher, Setpoint, United Rheumatology, AbbVie, ArthritisPower; K. Ford, Sanofi; S. Fiore, Sanofi; D. Isaman, Sanofi; L. Araujo, Sanofi; N. Petruski-Ivleva, Sanofi; F. Xie, Bendcare.